Skip to main content

Amgen becomes a Supporting Sponsor of the Cardiometabolic Center Alliance

The Cardiometabolic Center Alliance (CMCA), founded by Saint Luke’s Mid America Heart Institute, is honored to announce Amgen as a CMCA Supporting Sponsor.

As a coalition that seeks to establish Cardiometabolic Centers of Excellence nationwide aimed at transforming the treatment of type 2 diabetes (T2D), and related cardiovascular (CV) and renal comorbidities, the CMCA considers Amgen an important ally in the quest for improving the lives of those living with cardiovascular disease and diabetes. 

Cardiometabolic disease is one of the most vexing public health threats we face today. Improving guideline adherence and more effective implementation of efficacious therapies into clinical practice are critical to producing better patient outcomes and reducing complications. We are very excited to partner with Amgen to achieve these common goals, as we work to improve the quality of care in patients with cardiometabolic disease regardless of where they live,” said Mikhail Kosiborod, MD, Cardiometabolic Center Alliance Executive Director.

“We are very excited to support Saint Luke’s in the Cardiometabolic Center Alliance (CMCA). Cardiovascular disease is one of the largest public health concerns in the world, and at Amgen we are committed to support leading institutions to bring innovation to cardiovascular care,” said Ponda Motsepe-Ditshego, vice president of Global and U.S. Medical for Amgen’s General Medicine business unit. “The CMCA represents an excellent opportunity to bring evidence-based initiatives to clinical care while continuing collecting and generating insights that will ultimately improve the quality of care for those patients suffering of CV diseases.”


Alliance members will have adopted and implemented the novel care model designed and successfully implemented by Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence in Kansas City, MO. Based on the initial data, under this model the rates of optimal guideline-directed medical therapy substantially increased over the national average, ensuring that patients with T2D receive care that is aimed at both optimizing diabetes management and providing comprehensive cardiovascular risk reduction with therapies proven to improve outcomes. These results are made possible by a unified team of clinicians from across the disease continuum, who focus on holistic, guideline-directed preventative care. Through their participation, Alliance members are contributing to a national registry that will track treatment patterns and quality of care. As the Alliance enhances its capabilities, improves processes, and expands research opportunities on a national scale, the ultimate goal is improved patient outcomes.